Holen Sie sich die Stockscreener-App
6.385
11.26%
-0.81
Handel nachbörslich:
6.46
0.075
+1.17%
Precigen Inc Aktie (PGEN) Neueste Nachrichten
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike - Zacks Investment Research
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? - Zacks Investment Research
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Zacks Investment Research
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Zacks Investment Research
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Form 4 Precigen Inc For: 25 September By Investing.com - Investing.com Canada
Form 4 Precigen Inc For: 25 September - Investing.com India
Form 4 Precigen Inc For: 25 September By Investing.com - Investing.com UK
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
A treatment platform could help speed future drugs, Precigen says - Stock Titan
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026? - Yahoo Finance
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - Zacks Investment Research
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st
Precigen (PGEN) Director Jeffrey Kindler Sells 185,000 Shares - GuruFocus
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Nigeria
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Australia
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Canada
Precigen (PGEN) director sells 185K shares in one day - Stock Titan
Does Reliance On Papzimeos Skew Precigen’s (PGEN) Risk Profile Or Validate Its Focused Strategy? - Yahoo Finance
Is Precigen (PGEN) Undervalued After Reaching Quarterly Profitability? - sahmcapital.com
Precigen Director Sold Shares Worth Over $1.3M - TradingView
Precigen director Jeffrey Kindler sells $1.38m in stock - Investing.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Precigen (PGEN) director plans 185,000-share 2026 sale - Stock Titan
Precigen director Nancy H. Agee buys $24,661 of PGEN stock - investing.com
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com South Africa
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com Nigeria
Precigen CCO Phil Tennant sells $593,745 in stock By Investing.com - Investing.com Nigeria
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com India
Precigen Insider Sold Shares Worth $375,000, According to a Recent SEC Filing - marketscreener.com
Precigen (PGEN) insider lines up another stock sale after four recent trades - Stock Titan
Precigen (NASDAQ: PGEN) officer to sell 79,166 shares in 2026 - Stock Titan
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - Investing News Network
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - ACCESS Newswire
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - New Castle News
Precigen (PGEN) director adds 3,411 shares in open-market buy - Stock Titan
Precigen (PGEN) COO unloads 50K shares at $7.50 under plan - Stock Titan
Precigen Q2 Results: Profitability returns as PAPZIMEOS revenue doubles - scanx.trade
Precigen CCO Phil Tennant sells $593,745 in stock - Investing.com
Precigen COO Rutul Shah sells $375,000 in shares - Investing.com
0.84%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):